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Background/Objectives. Endothelial dysfunction due to hyperglycemia-induced oxidative damage is an important predictor of
future cardiovascular risk in patients with type 1 diabetes mellitus (T1DM) and is present in adolescent T1DM. We hypothesized
that combined treatment with the antioxidant vitamins C and E might improve endothelial function (EF) and other biochemical
risk factors in adolescents with T1DM. Subjects/Methods. Open-label antioxidant supplementation was given for six weeks with
endpoint measurements collected at baseline and study completion. Endpoints measured included EF and plasma measurements
of biochemical endothelial risk. Results. Two males and 7 females were studied. Mean age was 12.9 ± 0.9 yrs; mean T1DM duration
was 5.5 ± 2.5 yrs; mean BMI was 22.1 ± 3.8 kg/m2; and mean hemoglobin A1c was 9.3 ± 1.1%. No differences were found for
EF, high sensitivity CRP, total antioxidant capacity, adiponectin, or endothelial progenitor cells (EPCs) between before and after
combined vitamin C and E therapy.Conclusions. Our negative study results do not support previous findings of decreased oxidative
damage, improved endothelial function, and increased vascular repair capacity with antioxidant therapy. Longer term studies may
be needed to determine the effects, if any, of combined antioxidant therapy on EPCs, EF, and markers of micro- and macrovascular
complications in T1DM.
1. Introduction
Type 1 diabetes mellitus (T1DM) is a chronic medical condi-
tion requiring intensive treatment and optimal glycemic con-
trol in order to prevent and/or delay onset and/or progression
of long term complications. Cardiovascular disease (CVD) is
themajor cause of death for patients with T1DM in theUnited
States. The mortality and morbidity of CVD are strikingly
increased in individuals with T1DM compared to their
nondiabetic counterparts [1, 2] with a 6–13-fold higher risk
of cardiovascular death [3]. Atherosclerosis, themajor patho-
physiologic precursor of cardiovascular disease and ultimate
cause cardiovascular morbidity and mortality, begins in
childhood and adolescence [4]. Endothelial dysfunction is an
earlymarker of atherosclerosis that begins early in T1DM and
is directly involved in diabetes-induced microvascular and
macrovascular complications [1, 3, 5–9]. Although clinically
manifested diabetes-related microvascular (e.g., retinopathy,
nephropathy, and neuropathy) and macrovascular complica-
tions (e.g., cardiac disease and peripheral vascular disease)
are rare during childhood or adolescence, it is evident that
early potentially modifiable vascular functional and struc-
tural changes begin soon after diagnosis.
Endothelial dysfunction, vascular inflammation, build-
up of lipids, cholesterol, calcium, and cellular debris within
the intima of the vessel wall are characteristic features of
atherosclerosis [10]. The development of atherosclerosis in
T1DM begins in childhood and adolescence as a largely
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silent process as shown by increased intima-media thickness
(IMT) of the carotids and aorta [11, 12], impaired endothelial
function, and altered endothelial repair capacity. Impaired
endothelial function and altered endothelial repair have
been observed in T1DM. Previous studies have not only
found reduced flow mediated vasodilation [11, 13, 14], a
measure of endothelial function, but also decreased CD34+
CD133+ CD31+ circulating progenitor cells (CPCs) cells
with increased CD34+ CD45− endothelial colony form-
ing cells (ECFCs) [15], an indicator of altered endothelial
repair, in children and adolescents with T1DM. Additionally,
hyperglycemia-induced oxidative stress plays a pivotal patho-
physiological role in impairing endothelial function in T1DM
[6, 7]. Numerous studies have demonstrated that hyper-
glycemia not only increases free radicals but also impairs
endogenous antioxidant defense in T1DM. Children with
T1DM have evidence of increased oxidative stress in blood
and reductions in various aspects of antioxidant defense,
including reduced endogenous levels of vitamins C and E,
glutathione, decreased levels of superoxide dismutase, total
antioxidant capacity (TAC), increased levels of malondialde-
hyde, and oxidized LDL [16, 17].
While optimal glycemic control has been associated
with improved cardiac and peripheral vascular function and
the prevention of later vascular complications, discovering
a means of reducing or eliminating these early vascular
changes of CVD seen in childhood that is either independent
of or augmenting optimal glycemic control would be a
major medical breakthrough. Enhanced antioxidant intake
(either via diet or supplementation) may be one such means
of reducing the risk of diabetes-related microvascular and
macrovascular complications later in life, increasing the
lifespan and wellness, and reducing anxiety and frustration
in patients with T1DM.
The objective of this study was to determine effects
of antioxidant therapy, specifically vitamins C and E, on
antioxidant capacity, inflammatory markers (CRP and IL6),
and endothelial function, and define their interrelationships
in adolescents with T1DM. We also set out to determine the
effects of one month of combined antioxidant therapy on
numbers of endothelial colony forming cells (ECFCs: CD34+
CD133+CD45−) in adolescentswithT1DM.Wehypothesized
that antioxidant vitamin therapy would decrease oxidative
damage thereby improving endothelial function and increase
vascular repair capacity in adolescent T1DM.
2. Materials and Methods
2.1. Subjects. Nine children and adolescents aged 8–15 years
(mean age ± SD) with T1DM were included in this study.
These subjects were recruited from Pediatric Diabetes Clin-
ics Nationwide Children’s Hospital in Columbus, Ohio.
Informed consent was obtained from a parent or legal
guardian and informed assent was obtained from the subject.
The study was approved by the Institutional Review Board
of Nationwide Children’s Hospital. The initial diagnosis of
T1DM will have been made clinically. They must have been
started on insulin therapy immediately after diagnosis and
never have received an oral hypoglycemic agent.
For inclusion, subjects were between 8 and 15 years of
age with BMI ≤ 95% tile for age, pubertal stage of Tanner
stages 2–4, BP ≤ 95% tile for age, on insulin therapy since
diagnosis, fasting c-peptide <0.4 ng/mL, normal thyroid
function tests, random urine albumin to creatinine ratio
<0.02mg albumin/mg creatinine, and creatinine ≤1.0mg/dL.
Subjects with BMI ≥ 95% tile, BP > 95% tile, Tanner 1
or 5 pubertal status, pregnancy, smoking, history of oral
hypoglycemic use, acanthosis nigricans, fasting c-peptide
≥0.4 ng/mL, abnormal thyroid function tests, random urine
albumin to creatinine ratio ≥0.02mg albumin/mg creatinine,
creatinine >1.0mg/dL, or use of any medications other than
insulin, levothyroxine with stable dosage, or oral contracep-
tives were excluded from the study.
2.2. Protocol. Thiswas an open-label antioxidant supplemen-
tation for six weeks with endpoint measurements collected
at baseline and study completion. The subjects were seen
twice at the Clinical Research Center of the Clinical and
Translational Study Center of The Ohio State University. The
first visit occurred the morning after a minimum of 10-
hour fasting. Subjects were instructed to take their usual
insulin the day before their study visit and to take any
morning basal insulin. Subjects using continuous insulin
pump therapy were continued on their usual basal insulin
rates. Morning rapid acting insulin injection or insulin pump
boluses were held. Baseline blood samples were drawn for
total plasma antioxidant capacity (TAOC), high-sensitivity
C-reactive protein (hsCRP), and measurement of endothelial
progenitor cells (EPCs). Female participants were evaluated
during the first two weeks of their menstrual cycle in an
attempt tominimize the possible effects of hormonal changes
on endothelial function [18, 19]. Endothelial function was
then measured as described below. After completion of
the measurements subjects took their morning rapid acting
insulin injection or insulin pump bolus and were given
breakfast.The second study visit was identical to the first with
measurement of all endpoints. Subjects were instructed to
return all medications at visit two.
2.3. Endothelial FunctionMeasurement. Endotheliumdepen-
dent vasodilatory response was quantified as the mean pos-
tupper arm occlusion forearm vascular resistance (FVR) and
the percent change in forearm vascular resistance from pre-
to postocclusion. Forearm blood flow (FBF) was measured
using strain gauge venous occlusion plethysmography using a
HokansonAI6 plethysmograph. Twominutes of baseline FBF
was recorded after which the upper arm cuff was inflated to
200mmHg pressure for 5minutes to occlude flow. It was then
released and FBF was measured for one minute. FVR was
calculated by dividing mean arterial blood pressure by FBF.
Arterial blood pressure was measured using an automated
sphygmomanometer. This method of testing endothelial
function assesses resistance vessel function. Results closely
correlate with results from endothelial function assessed
by intra-arterial acetylcholine infusion [20] and correlate
well with the nitrite/nitrate ratio, an index of NO synthesis
[21].
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2.4. Vitamin Supplementation. Prior to discharge, subjects
were started on combined vitamins C and E. We scaled our
supplement dosing to account for subject size, as shown in
Table 1; these doses are equivalent to a dose of 1 g of vitamin C
and 400 IU of vitamin E per day in a 75 kg adult [16]. Subjects
were instructed to take the medication once daily and were
instructed to continue their routine diabetes care between
visits.
2.5. Laboratory Assays. High-sensitivity C-reactive protein
(hsCRP) and total plasma antioxidant capacity (TAOC), a
measure of oxidative stress, were measured for each subject
at their baseline fasting glucose level. TAOC is a nonspecific
assay of antioxidant defense which measures the ability
of constituents in plasma to absorb oxidation (BioVision
Research Products, Mountain View, CA). Adiponectin was
measured using a kit from R&D Systems Inc. Minneapo-
lis, MN, Cat. Number 1065. ECFCs were measured using
polychromatic flow cytometry methods. A 50𝜇L volume
anticoagulated peripheral bloodwas incubatedwith 50𝜇L 3%
BSA in PBS (without Ca++ and Mg++) at room temperature
for 30min. In dark, fluorescence labeled antibodies (2.5 𝜇L of
each), PE-AC133, FITC-CD34, andPECy5-CD45,were added
and incubated for 30min at room temperature. FACS lysis
buffer (450𝜇L) was then added and incubated for 30min
at room temperature in dark. Samples were then analyzed
on FACS Caliber flow cytometer, where total counts are
>400,000 cells. Intra-assay variability from ∼100 𝜇L whole
blood was <5%.
2.6. Statistical Analysis. Data were analyzed using a paired 𝑡-
test. Results are presented as mean ± SD.
3. Results
Two males and 7 females were studied. Mean age was
12.9 ± 0.9 years (range, 11.2 to 13.9 years): mean duration
of diabetes was 5.5 ± 2.5 years (range, 0.2 to 9.5 years);
mean BMI was 22.1 ± 3.8 kg/m2 (range 18.2 to 29.4 kg/m2);
and mean hemoglobin A1 was 9.3 ± 1.1% (range, 8.2% to
11.3%). No differences were seen in the FVR response to
occlusion between before and after combined vitamin C and
E therapy (Figure 1). No differences were seen in hsCRP,
TAOC, adiponectin, or EPC percent before or after vitamin
C and E therapy (Table 2).
4. Discussion
Oxidative stress plays a significant role in the chronic
complications of insulin-dependent diabetes mellitus. Our
study set out to determine the effects of antioxidant therapy
on antioxidant capacity, inflammatory markers, endothelial
function, and numbers of ECFCs, in adolescents with T1DM.
The oxidative stress that impairs endothelial function in
T1DM is induced by hyperglycemia [6, 7].This hyperglycemia
also impairs the endogenous antioxidant defense in T1DM.
Children with T1DM have evidence of reduced levels of
endogenous antioxidants vitamins C and E [16, 17]. Under
Table 1: Antioxidant dosage.
Dosing body weight Daily vitamin Cdose (mg)
Daily vitamin E
dose (IU)
<30 kg 250mg 100 IU
30–60 kg 500mg 200 IU
>60 kg 750mg 300 IU
Before After Before After
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Figure 1: FVR response before and after occlusion before and after
combined vitamin C and E therapy.
normal conditions, vitamin E suppresses the propagation of
lipid peroxidation and scavenges free radicals; and vitamin
C with vitamin E inhibits hydroperoxide formation; metal
complexing agents, such as penicillamine, bind transition
metals involved in some reactions in lipid peroxidation
and inhibit Fenton- and Haber-Weiss-type reactions (i.e.,
generating hydroxyl radicals (OH) from hydrogen peroxide
(H
2
O
2
) and superoxide (O2
−)) [22–25]. We hypothesized
that antioxidant vitamin therapy would decrease oxidative
damage thereby improving endothelial function and vascular
repair capacity in adolescent T1DM. This hypothesis proved
to be incorrect as we found no changes in postocclusive FVR,
hsCRP, TAC, adiponectin, or ECFCs.
Low vitaminC levels in type 1 diabetes are associated with
increased transcapillary albumin escape [26] and increased
atherosclerotic damage as evidenced by a negative relation-
ship to IMT in children [27]. Previous studies with ascorbic
acid (vitamin C) had suggested potential benefit. Antioxidant
treatment with acute intravenous ascorbic acid or 10 days of
oral ascorbic acid blocks the dilatory effect of hyperglycemia
on endothelial function during hyperglycemic clamp [28] or
oral glucose tolerance testing [29] in healthy adults. A 12-hour
ascorbic acid infusion restores endothelial function to normal
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Table 2: Biochemical markers and ECFCs at baseline and after 6 weeks of vitamin C and E therapy in adolescents with type 1 diabetes.
hsCRP (ng/mL) TAOC (Trolox equivalent/L) Adiponectin (ng/mL) ECFC (%)
Baseline 0.63 ± 0.85 95 ± 6 3970 ± 1150 0.027 ± 0.015
Vitamins C and E 0.74 ± 0.88 102 ± 12 4330 ± 1280 0.032 ± 0.037
levels in adults with recent onset or intermediate duration,
well-controlled type 1 diabetes [30, 31]. In patientswith poorly
controlled type 1 diabetes ascorbic acid infusion, alone,
only partially restores endothelial function. Acute ascorbic
acid infusion blocks the acute effects of hyperglycemia in
adolescents with type 1 diabetes [32].Therapeutically, vitamin
C decreases transcapillary albumin escape [26] and urinary
albumin excretion [33] in adults with T1DM. A previous
study by Varvaroksa et al. found in children with T1DM
the combination of vitamins C and E decreased hemoglobin
A1c and glycated protein levels and increased superoxide
dismutase and reduced glutathione [16]. However, based on
our results, combined vitamin C and E antioxidant intake
via supplementation did not improve endothelial function,
ECFCs, or other nontraditional risk factors.
Limitations of our study may include the short duration
of vitamin C and E supplementation for 6 weeks which
may have been inadequate to significantly decrease oxidative
damage, improve endothelial function, and increase vascular
repair capacity. The strategy (e.g., dosage and duration) was
chosen based on studies in adults, in many varying trials,
which showed that vitamin C (at doses 1 g/day or less) and
vitamin E (at doses of 400 IU/day or less) were consistently
shown to be safe and in many specific settings relevant to
this study to have efficacy in reducing oxidative stress in vivo
and/or affecting markers of disease. Our study utilized these
two supplements in combination, primarily since we do not
know if water soluble or fat soluble strategies are best in
this setting and since it is clear that these and other small
molecule antioxidants are compartmentalized in vivo and
interact to affect cellular redox status [34]. Also other studies
have suggested that lower doses of multiple antioxidants may
indeed be superior (and safer than) to mega doses of one
constituent [35–37]. Also our small sample size may not have
been large enough to demonstrate significant differences.The
lack of a normal control group is also another limitation to
this study. The differences seen were small and even with a
sample size large enough to find statistical significance are
unlikely to be of any clinical significance.
5. Conclusions
Our negative study results do not support previous findings
of decreased oxidative damage, improved endothelial func-
tion, and increased vascular repair capacity with antioxidant
therapy. Further research into other means of reducing or
eliminating vascular changes of CVD seen in childhood that
is either independent of or augmenting optimal glycemic
control is indeedwarranted. Ideally these studies would begin
at time of diagnosis of T1DM before the development of
diabetic complications. Longer term studies are necessary
to determine the effects, if any, of combined antioxidant
therapy on ECFCs, endothelial function, and markers of
microvascular and macrovascular complications in T1DM.
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